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Background
Cancer cells reprogram their metabolism for optimal
growth and survival. Identifying the genes and their func-
tions crucial for cancer metabolic reprograming might
have therapeutic implications. The multifunctional kinase
AMPK is an evolutionarily conserved energy sensor that
plays an important role in cell proliferation, growth and
survival. It remains unclear whether AMPK functions as
a tumor suppressor or a contextual oncogene. This is
because while on one hand active AMPK inhibits mTOR
and lipogenesis - two crucial arms of cancer growth,
AMPK also ensures viability during metabolic stress.
Many studies have shown that AMPK activation by two
indirect AMPK agonists AICAR and metformin (now in
many cancer clinical trials) reduces cancer cell prolifera-
tion - an effect that is rescued by an AMPK inhibitor
Compound C in some studies. We used genetic models
to scrutinize the specificity of these reagents and examine
whether AMPK is a growth suppressor in glioblastoma.
Materials and methods
We used silencing RNA against AMPK in established
GBM cell lines and examined viability in the presence or
absence of the reagents to define their mechanisms of
action.
Results
Surprisingly, we found that compared to normal tissue,
AMPK is constitutively active in both human and mouse
gliomas in vivo. We found that both AMPK agonists inhib-
ited proliferation, but through discrete AMPK-independent
mechanisms and both reagents reduced GBM growth
in vivo independent of AMPK. Importantly, A769662, a
new and direct AMPK activator had no effect on GBM cell
proliferation. Metformin directly inhibited mTOR by
enhancing PRAS40 association with RAPTOR, while
AICAR blocked cell cycle through proteasomal degradation
of the G2M phosphatase cdc25c. In another surprise,
Compound C itself proved to be a potent anti-GBM agent;
however, its cell killing effects were pleiotropic and also
independent of AMPK. We next examined if AMPK is
required for viability of freshly established patient-derived
GBM cells and found that many of these cells lose viability
in vitro when AMPK was silenced.
Conclusions
Our results suggest that AICAR, metformin and Com-
pound C are all AMPK-independent anti-proliferative
agents. Importantly, physiologically active AMPK in GBM
could be a growth promoter rather than a growth suppres-
sor in vivo. We are taking multiple genetic approaches to
determine this in mouse models of human GBM.
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